TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26813845
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBTi)
Study: 18992162
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy (RT)
Study: 16531163
Drug: ethinylestradiol 30
Normalized name: Drospirenone 3 mg and ethinylestradiol 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethinylestradiol 30 mug/drospirenone 3 mg (EE/DRS)
Study: 10950230
Drug: Malathion lotion
Normalized name: Malathion Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malathion lotion (0.5%) applied twice, 7 days apart
Study: 8825255
Drug: Integrated service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated service agencies (ISAs) with financing reform and assertive continuous treatment team approach
Study: 1563207
Drug: Bidisomide (SC-40230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidisomide (SC-40230) intravenous doses ranging from 0.03 to 2.5 mg/kg
Study: 1563207
Drug: Bidisomide (SC-40230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bidisomide (SC-40230) 2.0 mg/kg orally and intravenously
Study: 6362417
Drug: Extraperitoneal cesarean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraperitoneal cesarean section plus prophylactic antibiotics (group C)
Study: 25683592
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg daily)
Study: 31066956
Drug: Urethral bulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral bulking therapy
Study: 22964561
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT) for 12 months
Study: 22964561
Drug: DBT (completed
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBT (completed treatment)
Study: 17928325
Drug: Albendazole 15
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 15 mg/kg/day for 2 weeks
Study: 17928325
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cysticidal therapy)
Study: 8556997
Drug: Rocuronium as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium as a priming agent
Study: 8556997
Drug: Rocuronium and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium and vecuronium as priming agents
Study: 1930849
Drug: 15 mmol
Normalized name: dibasic potassium phosphate 15 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mmol Mg added to a free diet for 6 months
Study: 19700248
Drug: Conventional (tangential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (tangential field) fractionated whole breast treatment (Arm A)
Study: 15833589
Drug: Cortisol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (0.5 mg/kg)
Study: 7759146
Drug: BioLogic-DT sorbent
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BioLogic-DT sorbent suspension dialyser
Study: 2856651
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human growth hormone releasing factor (hGRF) (1 microgram/kg in 5 cc of normal saline infused over five minutes)
Study: 2856651
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human growth hormone releasing factor (hGRF)
Study: 30965599
Drug: BoNT‐A combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A combined with a four‐week ankle isokinetic treatment (n = 12)
Study: 2328112
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (3 drops, 250 micrograms/mL in saline solution) locally twice a day (group B)
Study: 2328112
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of topical ciprofloxacin and oral ciprofloxacin (group C)
Study: 2328112
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (250 mg orally twice a day) (group A)
Study: 6102409
Drug: Floctafenine 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenine 1.2 g daily
Study: 27453081
Drug: Combination (COMB)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (COMB)
Study: 23834253
Drug: Synthetic extracellular
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic extracellular matrix protein as an adjunct to standard care
Study: 17635734
Drug: Combined anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined anticoagulant and antiplatelet therapy
Study: 22398668
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel
Study: 12445486
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion (30 microg/30 min)
Study: 9435411
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rHGH) 0.2 mg/kg.day
Study: 9435411
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rHGH)
Study: 8085776
Drug: Diltiazem LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem LP 300 mg (morning administration)
Study: 8085776
Drug: Diltiazem LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem LP 300 mg (evening administration)
Study: 8085776
Drug: Diltiazem LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem LP 300 mg (both morning and evening)
Study: 30511840
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (n = 41, 4 capsules/day, equivalent to 2 g of eicosapentaenoic acid plus docosahexaenoic acid)
Study: 26447153
Drug: 25(OH)D concentration
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentration ≥30 ng/mL in former and current smokers
Study: 21282528
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation (control group) with no extra therapy
Study: 19411747
Drug: Antidepressant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant and psychological intervention
Study: 7857354
Drug: Pidotimod (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (400 mg oral bottle daily)
Study: 1054855
Drug: 0.5% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% chlorhexidine gluconate gel
Study: 18082830
Drug: Sodium dodecyl
Normalized name: Sodium dodecyl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium dodecyl sulfate polyacrylamide gel electrophoresis with silver staining
Study: 2979690
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg intravenous)
Study: 25329159
Drug: n‐3 long‐chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 long‐chain polyunsaturated fatty acids (n‐3 LCPUFA) 4 g daily for 8 weeks
Study: 25329159
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (OO) 4 g daily for 8 weeks
Study: 11256057
Drug: Five structured
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five structured clinical interviews (SCI-PAS, SCI-MOODS, SCI-SHY, SCI-OBS, SCI-ABS) administered along with a diagnostic interview and self-report instruments.
Study: 9346220
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2 over 3 hours) with carboplatin (AUC 5)
Study: 9346220
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2 over 3 hours) with cisplatin (75 mg/m2)
Study: 8452174
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg orally once daily for 4-21 days
Study: 8452174
Drug: Amoxicillin/clavulanate potassium
Normalized name: Amoxicillin/Clavulanate Potassium 250 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate potassium (AMX/CP) 500 mg/125 mg orally three times daily for 4-21 days
Study: 8888359
Drug: D-amphetamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (0.5 mg/kg)
Study: 3287703
Drug: Pentoxifylline (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (16 mg/kg/day IV for 3 days, then 400 mg t.i.d. for 28 days)
Study: 26250486
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg as tablet for 6 weeks)
Study: 24558759
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 5.0 mg/kg (group A)
Study: 24558759
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 7.5 mg/kg (group B)
Study: 21332932
Drug: Etoricoxib 30
Normalized name: Etoricoxib 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 30 mg/day
Study: 23748324
Drug: TiUnite implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiUnite implants
Study: 17100744
Drug: Turned implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turned implants
Study: 15301100
Drug: Liquefacient nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquefacient nitrogen cryotherapy with antibiotic eye drops and ointments
Study: 9329359
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (OCT) treatment (150-600 micrograms/day for 3-6 months)
Study: 9329359
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (OCT) treatment
Study: 24247476
Drug: Glucagon-like peptide-1
Normalized name: Glucagon-like peptide-1 (GLP-1) analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide-1 (1.5 pmol/kg/min) plus intensive insulin therapy
Study: 24247476
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline plus intensive insulin therapy
Study: 20673995
Drug: Naltrexone 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 32 mg plus bupropion 360 mg per day
Study: 20673995
Drug: Naltrexone 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 16 mg plus bupropion 360 mg per day
Study: 23726126
Drug: Multiphasic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiphasic injection protocol (protocol I) with 89 mL of Optiray 350
Study: 23726126
Drug: Test bolus
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test bolus injection protocol (protocol II) with a 10 mL test bolus of Optiray 350 followed by 40 mL of contrast medium
Study: 19485286
Drug: Topical cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporin A 1%
Study: 8451895
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g Cefoxitin
Study: 8451895
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g Cefuroxim
Study: 20103314
Drug: Both heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both heparin groups (low-dose and high-dose)
Study: 15961531
Drug: Control (saline;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline; rate 4 ml/min)
Study: 9695210
Drug: ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftazidime 2 g every 8 h plus amikacin 15 mg/kg i.v. per day
Study: 2671218
Drug: Topical Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Bupivacaine 0.5 per cent solution
Study: 776539
Drug: tolmetin 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolmetin 1200 mg per day
Study: 776539
Drug: tolmetin 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolmetin 1400 mg daily
Study: 776539
Drug: indomethacin 150
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indomethacin 150 mg daily
Study: 6634894
Drug: Hydrocortisone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (20 mg)
Study: 31689951
Drug: Placebo (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3.5 g inert stevia)
Study: 24235245
Drug: 15% propolis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% propolis solution
Study: 16885888
Drug: Topical antiallergic
Normalized name: Other antiallergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiallergic treatment (membrane stabilizer or antihistamine)
Study: 15491434
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus plus salicylic acid
Study: 2898227
Drug: Intracerebroventricular (ICV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracerebroventricular (ICV) cholinergic drug infusion (bethanechol chloride)
Study: 15969668
Drug: Low-dose peanut
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose peanut challenge
Study: 10695096
Drug: nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine retard 10 mg twice daily
Study: 6801218
Drug: Intracranial pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracranial pressure monitoring and aggressive treatment (including mannitol therapy and drainage of cerebrospinal fluid)
Study: 6801218
Drug: ICP monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICP monitoring with aggressive treatment
Study: 27166670
Drug: Annual prostate‐specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual prostate‐specific antigen (PSA) screening for 6 years and digital rectal examination for 4 years
Study: 23775532
Drug: Totally extraperitoneal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Totally extraperitoneal patch (TEP) hernioplasty
Study: 23775532
Drug: Open tension‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open tension‐free plug and patch (PP) technique
Study: 17894706
Drug: Continuous cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cyclosporine (CyA) therapy at individualized effective doses
Study: 17894706
Drug: Intermittent cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclosporine (CyA) therapy
Study: 17894706
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment schedules
Study: 15250006
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (control group)
Study: 7677459
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion for 7 days
Study: 31132908
Drug: Tablet and
Normalized name: TABLET AND CAPSULE, DOSE PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet and pen version
Study: 31132908
Drug: Tablet and
Normalized name: TABLET AND CAPSULE, DOSE PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet and finger version
Study: 27493198
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fexofenadine and ranitidine (blockade)
Study: 26187277
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) adjunctive treatment for fractures, including Shu-jing-huo-xue-tang and Rhizoma Drynariae (Gu-sui-bu) as common prescriptions.
Study: 20347079
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (IMP)
Study: 7766738
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 50 micrograms of octreotide
Study: 2277579
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 3 mL normal saline into the P6 acupuncture point after anesthesia
Study: 15781835
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of levetiracetam
Study: 9346622
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime and flucloxacillin plus oral and enteral decontamination with colistin, tobramycin, and amphotericin B (group 1)
Study: 1869454
Drug: Hyperfractionated RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated RT (70.4 Gy in 64 fractions of 1.1 Gy given twice a day)
Study: 31338732
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches for 6 weeks
Study: 29408562
Drug: High-intensity lifestyle
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity lifestyle intervention delivered by health coaches; 16 in-person sessions and 6 telephone sessions in the first 6 months, followed by at least monthly sessions for 18 months.
Study: 29408562
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care provided by primary care practitioners with information on weight management and reimbursement for obesity treatment.
Study: 27080034
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg daily on-demand
Study: 27080034
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg daily continuously
Study: 21900941
Drug: Aliskiren 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 75 mg
Study: 12100802
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous meperidine
Study: 10626032
Drug: 44 mg/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 mg/24 hour nicotine patch for 4 weeks
Study: 10626032
Drug: 22 mg/24
Normalized name: ProStep, 22 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg/24 hour nicotine patch for 6 weeks
Study: 10626032
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention (minimal, brief individual counseling, group therapy)
Study: 7847611
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g ethanol/kg body weight
Study: 7847611
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g ethanol/kg body weight
Study: 1493666
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (group 1)
Study: 27033026
Drug: omega‐3 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega‐3 (4 g/day) and vitamin E (400 IU/day)
Study: 25471216
Drug: Iron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (50 mg) supplementation
Study: 25471216
Drug: Iron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron (50 mg) + DHA (420 mg) + EPA (80 mg) supplementation
Study: 9506873
Drug: Multimodal cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cognitive behavioral treatment (MMCBT) for 4 weeks
Study: 9506873
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ordinary treatment through general practitioners)
Study: 3290578
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using Flutamide and LHRH agonist [D‐Trp6]LHRH ethylamide
Study: 29778106
Drug: Topical bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bromfenac 0.09% twice daily for 2 weeks
Study: 29778106
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone 0.1% 4 times daily with tapering
Study: 29778106
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of topical bromfenac 0.09% and dexamethasone 0.1%
Study: 7668872
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with MMC 12 mg/m2 on the day of operation, followed by 6 mg/m2 every two months for 6 times, and FT 800 mg/body/day for one year.
Study: 7668872
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in rectal cancer cases, specifically Dukes C cases.
Study: 20131073
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity diode laser adjunct to root scaling and planing
Study: 338255
Drug: feprazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: feprazone (600 mg/day)
Study: 338255
Drug: ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen (1200 mg/day)
Study: 26431977
Drug: PACT (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACT (100 μg mL(‐1) TBO followed by 94J cm(‐2) LED irradiation)
Study: 23258380
Drug: Bleaching agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleaching agent
Study: 23258380
Drug: Peroxide‐free bleaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroxide‐free bleaching agent